TrialActa neuropathologica communications2018

Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.

Friedrich Erhart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.